The efforts of individual researchers, laboratories, cross-disciplinary programs, and focused areas of investigation all contribute to the research goals of the UCSF Helen Diller Family Comprehensive Cancer Center.
Lab scientists, clinical investigators, epidemiologists, and providers of patient care work collaboratively in program areas. See individual program listings for program leaders, goals, and current research initiatives.
State-of-the-art support services and technology provide investigators with tools to facilitate the achievement of their research goals.
Specialized Programs Of Research Excellence (SPOREs), sponsored by the National Cancer Institute, are prestigious initiatives that engage lab-based and population scientists, clinical investigators, and advocates in focused areas of research.
The Investigational Trials Resource (ITR) is an organizational unit within the Helen Diller Family Comprehensive Cancer Center (HDFCCC) which was launched in 2007 with the goal of centralizing and streamlining the HDFCCC’s clinical research infrastructure and increasing patient accrual.
|
Faculty investigators in laboratory, clinical, and population-based research represent more than 50 departments and institutes in the UCSF Schools of Medicine, Pharmacy, Dentistry, and Nursing. Members comprise a distinguished group of researchers whose collaborations embody our mission and research goals.
|
Approximately half of the Cancer Center’s faculty members conduct laboratory research at UCSF and other Bay Area institutions.
|
Additional Cancer Research at UCSF
-
Cancer Immunotherapy Program
The UCSF Cancer Immunotherapy Program and Clinic brings together clinicians and scientists from across multiple disciplines into a single, streamlined program in order to develop novel approaches to treating cancer. Its research examines the effect of immune-based therapies on various markers of the immune system and the subsequent impact this has on cancer cells. This research will inform pioneering efforts to rapidly translate new scientific discoveries into tangible clinical benefits for patients.
-
Cancer Risk Program
The UCSF Cancer Risk Program, part of the UCSF Helen Diller Family Comprehensive Cancer Center, identifies families and individuals at high risk for colorectal, breast, ovarian, and prostate cancer by analysis of the family cancer pedigree, assessment of heritable risk, and testing for specific genetic mutations.
-
Center for BRCA Research
The Center for BRCA Research provides a unique model of research and care for cancer patients with hereditary cancers due to BRCA and other genetic mutations.
-
Center for Evolution and Cancer
The CEC brings together researchers from across the world to accelerate progress in cancer research, with the goal of employing evolutionarily informed approaches to advance cancer research, cancer prevention, and patient management.
-
Melanoma Program
The UCSF Helen Diller Family Comprehensive Cancer Center Melanoma Program is a specialty service that manages all stages of melanoma, from diagnosis of early lesions to therapy for late-stage disease. This program offers a multidisciplinary approach to the diagnosis and management of melanoma.
-
Multiple Myeloma Program
The Multiple Myeloma Program at UCSF is a comprehensive program that includes a clinical arm with physicians available for patient consultation and management of the disease, a clinical research arm that provides access to the very latest in new drugs and new therapies, a basic research arm that is actively identifying new targets and new agents for therapy, and a translational component dedicated to understanding the disease more fully, as well as to bringing these new agents rapidly to the clinic to be able to help our patients. Includes the UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative (Grand MMTI).
-
Pancreas Program
The Pancreas Program is comprised of a multidisciplinary group of investigators focused on pancreatic cancer.
-
Precision Imaging for Cancer and Therapy
The PICT Program brings together basic, translational, and clinical scientists in order to integrate cutting edge, multi-modality imaging into all aspects of patient care and cancer research.
